Actively Recruiting
Evaluating Bicalutamide with Intravesical BCG in Males with Non-Muscle Invasive Bladder Cancer A Phase II Randomized Trial
Led by CHU de Quebec-Universite Laval · Updated on 2026-10-26
160
Participants Needed
7
Research Sites
34 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating treatment options for males with non-muscle invasive bladder cancer NMIBC, which is the most common form of bladder cancer. This phase II clinical trial compares the standard intravesical bacillus Calmette-Gurin BCG treatment alone to BCG combined with the drug bicalutamide. The study aims to see if adding bicalutamide can reduce the rate of cancer recurrence, as approximately 30-40% of patients relapse or progress despite standard treatment. The trial includes two cohorts. Cohort A involves about 40 participants and is open-label, while cohort B has about 120 participants and is double-blind with placebo control. In both cohorts, participants receive 6 cycles of BCG instillations. Cohort A participants are randomized to either BCG plus 150 mg daily bicalutamide for 3 months or BCG alone. In cohort B, participants are randomized to BCG plus bicalutamide or BCG plus placebo daily for 3 months. The study treatments overlap during the 3 months of oral medication and BCG instillations. Participants are involved for up to 36 months from screening to last follow-up. During this time, researchers will monitor bladder tumor recurrence rates, tumor progression, number of recurrences, and quality of life including urinary symptoms. The study includes regular assessments to track these outcomes and evaluate the safety and effects of combining bicalutamide with standard BCG therapy.
CONDITIONS
Brief Title
A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer
Research Team
P
Paul Toren, MD,PhD,FRCSC
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here